ALG-LungCancerRegistry (SAFRO2202)

Key facts

Sponsor

Société Algérienne de Formation et de Recherche en Oncologie

Principal Investigator

Adda BOUNEDJAR, Professor of Medical Oncology

Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria

Intervention

Observational Data Collection(other)

Enrollment

3750 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2027

Study locations (21)

• Centre Pierre et Marie Curie, Algiers, Algiers Province, Algeria
• Chu Beni Messous - Isaad Hassani, Algiers, Algiers Province, Algeria
• CHU Mohamed Lamine Debaghine - Bab-el-Oued, Algiers, Algiers Province, Algeria
• Chu-Beni Messous - Isaad Hassani, Algiers, Algiers Province, Algeria
• EPH Rouiba, Algiers, Algiers Province, Algeria
• CLCC Annaba, Annaba, Annaba, Algeria
• CLCC Batna, Batna City, Batna, Algeria
• CAC-CHU Frantz Fanon, Blida, Blida Province, Algeria
• CHU- Hôpital Khelil Amrane, Béjaïa, Béjaia Province, Algeria
• CHU Dr Abdesselam Benbadis, Constantine, Constantine Province, Algeria
• EH Didouche Mourad, Constantine, Constantine Province, Algeria
• CLCC Draâ Ben Khedda, Tizi Ouzou, Draâ Ben Khedda, Algeria
• CAC-Laghouat, Laghouat, Laghouat Province, Algeria
• CAC Oran EL HASSI- EMIR ABDELKADER, Oran, Oran Province, Algeria
• CHU Dr. Benaouda Benzerdjeb, Oran, Oran Province, Algeria
• +6 more locations on ClinicalTrials.gov

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gastroenteric neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT03110978
  Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
  M.D. Anderson Cancer Center

See all trials for Gastroenteric neuroendocrine neoplasm →